Try our beta test site

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease (EXPEDITION EXT)

This study has been terminated.
(Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.)
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01127633
First received: May 19, 2010
Last updated: March 7, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2017
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: September 29, 2014